TNF-α-secreting B cells contribute to myocardial fibrosis in dilated cardiomyopathy

Journal of Clinical Immunology

Volumn 33, Issue 5, 2013, Pages 1002-1008

  Yu, Miao ^a   Wen, Shuang ^a   Wang, Min ^a   Liang, Wei ^a   Li, Huan Huan ^a   Long, Qi ^a   Guo, He Ping ^a   Liao, Yu Hua ^a   Yuan, Jing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

B cells; inflammation; myocardial fibrosis; TNF

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GADOLINIUM; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROCOLLAGEN; PROCOLLAGEN TYPE 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC DIAMETER; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; B-LYMPHOCYTES; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CELL GROWTH PROCESSES; COLLAGEN TYPE III; FEMALE; FIBROSIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879247291     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-013-9889-y     Document Type: Article

References (25)

1. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet. 2010;375:752-62.
2. Sagar S, Liu PP, Cooper LT. Myocarditis. Lancet. 2012;379:738-47.
3. Schwarz F, Mall G, Zebe H, Blickle J, Derks H, Manthey J, et al. Quantitative morphologic findings of the myocardium in idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:501-6.
4. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev. 2008;223:284-99.
5. Youinou P, Taher TE, Pers JO, Mageed RA, Renaudineau Y. B lymphocyte cytokines and rheumatic autoimmune disease. Arthritis Rheum. 2009;60:1873-80.
6. Lund FE. Cytokine-producing B, lymphocytes-key regulators of immunity. Curr Opin Immunol. 2008;20:332-8.
7. Yuan J, Cao AL, Yu M, Lin QW, Yu X, Zhang JH, et al. Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis. J Clin Immunol. 2010;30:226-34.
8. Vilahur G, Juan-Babot O, Peña E, Oñate B, Casaní L, Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol. 2011;50:522-33.
9. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841-2.
10. Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, et al. Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3-induced acute viral myocarditis. Int Immunopharmacol. 2010;10:272-6.
11. Aukrust P, Yndestad A, Damås JK, Gullestad L. Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin. Autoimmun Rev. 2004;3:221-7.
12. Blyszczuk P, Kania G, Dieterle T, Marty RR, Valaperti A, Berthonneche C, et al. Myeloid differentiation factor-88/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ Res. 2009;105:912-20.
13. Wei L. Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis. Exp Mol Pathol. 2011;90:74-8.
14. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS. Ann Neurol. 2010;67:452-61.
15. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation. J Immunol. 2004;172:3422-7.
16. Vazquez-Tello A, Halwani R, Li R, Nadigel J, Bar-Or A, Mazer BD, et al. IL-17A and IL-17F expression in B lymphocytes. Int Arch Allergy Immunol. 2012;157:406-16.
17. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res. 2010;106:1646-55.
18. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res. 2000;86:1259-65.
19. Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005;280:36099-109.
20. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res. 2005;65:40-51.
21. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4 (+) T cell immunity. Nat Rev Immunol. 2010;10:236-47.
22. Liao YH, Yuan J, Wang ZH, Cheng X, Zhang JH, Tian Y, et al. Infectious tolerance to ADP/ATP carrier peptides induced by anti-L3T4 monoclonal antibody in dilated cardiomyopathy mice. J Clin Immunol. 2005;25:376-84.
23. Brunetti ND, D'Antuono C, Rana M, D'Arienzo G, De Gennaro L, Di Biase M. Lymphocyte subset characterization in patients with early clinical presentation of coronary heart disease. J Thromb Thrombolysis. 2012;34:475-82.
24. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044-7.
25. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF Therapy against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-40.